Seres Therapeutics, Inc.
NASDAQ:MCRBBiotechnology
+$0.11 today
- Market cap
- $51.13M
- Beta
- 0.11
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$4.89
Volume 0.04M
Average 0.06M
MCRB Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Seres Therapeutics, Inc.NASDAQ: MCRB
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns negative
Q1 FY2026 net income was -$19.91M, compared with $32.68M a year earlier. Trailing-twelve-month net income was -$46.9M.
Context
- Net income amounted to 721.9% of revenue in FY2025.
- Net income increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$37.49M (-758.1%) for the fiscal year ending Dec 2026, a slowdown from the +4088.2% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$19.91M+29.9% QoQ
- Last fiscal yearDec 2025
- $5.7M+4088.2% YoY
- LTMMar 2026
- -$46.9M-164.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -160.9% | +6.1% | +167.1 pp |
| 1 year | +4088.2% | -758.1% | -4846.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 5.7M USD
- Year-over-year change
- +4088.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.7M | +4088.2% |
| FY2024 | 2024-12-31 | 136K | +100.1% |
| FY2023 | 2023-12-31 | (113.72M) | +54.5% |
| FY2022 | 2022-12-31 | (250.16M) | -281.5% |
| FY2021 | 2021-12-31 | (65.58M) | — |
Net Income vs competitors
How MCRB compares with its peers on the latest reported figures
- MCRB's LTM Mar 2026 net income of $46.9M is the 5th largest of the 9 companies compared; the peer median is $50.71M.
- Its year-over-year change of -164.3% is the lowest of 8, against a peer median of -12.0%.
- Net income amounts to 4088.8% of revenue for MCRB, versus a peer median of 468.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $113.28M | -2.6% | +41.5% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $106.93M | +82.4% | — | 892.4% |
| LTM Mar 2026 | $84.93M | -12.0% | -32.8% | — | |
| LTM Mar 2026 | $70.49M | -17.9% | -7.5% | 468.7% | |
| LTM Mar 2026 | $46.9M | -164.3% | — | 4088.8% | |
| LTM Mar 2026 | $30.92M | — | +47.5% | — | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $21.54M | -14.9% | +3.3% | — |
| LTM Mar 2026 | $19.58M | -41.2% | +3.2% | — | |
| LTM Mar 2026 | $15.24M | +121.8% | — | 27.8% | |
| Peer median (excluding MCRB) | $50.71M | -12.0% | +3.2% | 468.7% | |
Competitors are the stored peer set for MCRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (65.58M) | (250.16M) | (113.72M) | 136K | 5.7M |
| Depreciation & Amortization | 5.95M | 6.63M | 6.24M | 5.47M | 4.13M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 20.22M | 25.48M | 34.1M | 20.97M | 10.84M |
| Change in Working Capital | 41.53M | (18.39M) | (58.98M) | (65.51M) | (27.78M) |
| Accounts Receivables | 9.39M | 0 | (8.67M) | (2.07M) | 1.55M |
| Inventory | 0 | 0 | (29.65M) | (33.8M) | 0 |
| Accounts Payables | 9.36M | 2.2M | (11.58M) | (2.94M) | (2.4M) |
| Other Working Capital | 22.78M | (20.59M) | (9.08M) | (26.71M) | (26.93M) |
| Other Non-Cash Items | 4.57M | 7.62M | 15M | (109.68M) | 8.23M |
| Operating Cash Flow | 6.69M | (228.82M) | (117.35M) | (148.61M) | 1.12M |
| Capital Expenditures | (9.57M) | (9.82M) | (7.98M) | (380K) | (252K) |
| Acquisitions (Net) | 0 | (92.25M) | 0 | 0 | 210K |
| Purchases of Investments | (95.97M) | (48.22M) | (4.43M) | 13.52M | 0 |
| Sales of Investments | 169.63M | 140.47M | 22.98M | 142.67M | 0 |
| Other Investing Activities | 0 | 92.25M | 0 | (13.52M) | 0 |
| Investing Cash Flow | 64.09M | 82.43M | 10.58M | 142.29M | (42K) |
| Debt Repayment | (948K) | 25.7M | 50.52M | (127.91M) | 0 |
| Common Stock Issued | 2.13M | 101.17M | 18.16M | 23.53M | 13.9M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.13M | 2.74M | 3.03M | 14M | 0 |
| Financing Cash Flow | 1.18M | 129.6M | 71.71M | (90.37M) | 13.9M |
| Effect of Forex Changes | (1K) | (1K) | 2K | (1K) | 0 |
| Net Change in Cash | 71.95M | (16.79M) | (35.07M) | (96.69M) | 14.97M |
| Free Cash Flow | (2.88M) | (238.64M) | (125.33M) | (148.99M) | 865K |
Seres Therapeutics, Inc.
NASDAQ:MCRB
Intrinsic Alpha fair value
Locked
Current Price
$5.28
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.